{"id":449112,"date":"2025-09-18T12:07:21","date_gmt":"2025-09-18T10:07:21","guid":{"rendered":"https:\/\/medizinonline.com\/monarche-5-year-data\/"},"modified":"2026-04-16T14:48:22","modified_gmt":"2026-04-16T12:48:22","slug":"monarche-7-year-data","status":"publish","type":"page","link":"https:\/\/medizinonline.com\/it\/monarche-7-year-data\/","title":{"rendered":"MonarchE 7-Year Data"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1160\" height=\"244\" src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/03\/Picture-21-1160x244.png\" alt=\"\" class=\"wp-image-552665\" srcset=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/03\/Picture-21-1160x244.png 1160w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/03\/Picture-21-800x168.png 800w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/03\/Picture-21-1120x235.png 1120w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/03\/Picture-21.png 1451w\" sizes=\"(max-width: 1160px) 100vw, 1160px\" \/><\/figure>\n\n\n\n<h4 id=\"a-new-milestone-reached-in-early-breast-cancer-care-in-switzerland\" class=\"wp-block-heading\">A new milestone reached in early breast cancer care in Switzerland!<\/h4>\n\n\n\n<h4 id=\"verzenios-abemaciclib-now-listed-on-the-specialties-list-sl-for-reimbursement-for-hr-her2-early-breast-cancer-with-a-high-risk-of-recurrence5\" class=\"wp-block-heading\">Verzenios\u00ae (abemaciclib) \u2013 Now listed on the Specialties List (SL) for reimbursement for HR+, HER2\u2011 early breast cancer with a high risk of recurrence<sup>*,5<\/sup><\/h4>\n\n\n\n<p>Verzenios\u00ae is already reimbursed on the Specialties List for the treatment of female patients with <strong>HR+, HER2\u2011 locally advanced or metastatic breast cancer (MBC)<\/strong> and now officially <strong>extends access to the adjuvant setting in early breast cancer<sup>4,5<\/sup><\/strong>.<\/p>\n\n\n\n<h4 id=\"indication4-5\" class=\"wp-block-heading\">Indication<sup>4-5<\/sup><\/h4>\n\n\n\n<p>Verzenios\u00ae is indicated for the treatment of <strong>adult female patients with HR+ HER2-, node positive early breast cancer at high risk of recurrence*<\/strong>, based on the <strong>monarchE study criteria (Cohort 1)<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>\u2265 4 positive axillary lymph nodes<\/strong>, or<\/li>\n\n\n\n<li><strong>1\u20133 positive axillary lymph nodes<\/strong> and <strong>tumor size \u2265 5 cm<\/strong>, <strong>histological grade 3<\/strong>, or <strong>both<\/strong><\/li>\n<\/ul>\n\n\n\n<p>Verzenios\u00ae is used in <strong>combination with endocrine therapy<\/strong>; in pre\u2011 or perimenopausal women, this must be administered with an aromatase inhibitor in combination with an LHRH agonist.<\/p>\n\n\n\n<h4 id=\"reimbursement-framework5\" class=\"wp-block-heading\">Reimbursement Framework<sup>5<\/sup><\/h4>\n\n\n\n<p>According to the Specialties List, reimbursement includes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Verzenios\u00ae film\u2011coated tablets<\/strong> (50 mg, 100 mg, 150 mg)<\/li>\n\n\n\n<li><strong>Treatment regimen<\/strong>: 150 mg twice daily as continuous therapy following complete resection of the primary tumour and completion of (neo)adjuvant chemotherapy \u2013 Verzenios therapy is limited to a maximum of 24 months (26 cycles of 28 days each) or until disease progression or the occurrence of unacceptable toxicity.<\/li>\n<\/ul>\n\n\n\n<p>Prior to initiation of therapy, a cost approval from the health insurer must be obtained following prior consultation with the medical advisor; this approval must include indication code 20839.04.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1160\" height=\"132\" data-src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/03\/Picture-451-1160x132.jpg\" alt=\"\" class=\"wp-image-552667 lazyload\" data-srcset=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/03\/Picture-451-1160x132.jpg 1160w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/03\/Picture-451-800x91.jpg 800w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/03\/Picture-451-1120x128.jpg 1120w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/03\/Picture-451.jpg 1384w\" data-sizes=\"(max-width: 1160px) 100vw, 1160px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 1160px; --smush-placeholder-aspect-ratio: 1160\/132;\" \/><\/figure>\n\n\n\n<p>For further information, please visit: <a href=\"http:\/\/www.swissmedicinfo.ch\" target=\"_blank\" rel=\"noopener\"><strong>www.swissmedicinfo.ch<\/strong><\/a> and <a href=\"http:\/\/www.spezialit\u00e4tenliste.ch\" target=\"_blank\" rel=\"noopener\"><strong>www.spezialit\u00e4tenliste.ch<\/strong><\/a><\/p>\n\n\n\n<p>**Swiss label only for cohort 1: \u2265 4 positive axillary lymph nodes or 1-3 positive axillary lymph nodes and tumors that were \u2265 5 cm, histological Grade 3 or both.&nbsp; In Cohort 1 0.6 % of patients were male.&nbsp; Male population was excluded for the Swiss approval.<sup>2,3<\/sup><\/p>\n\n\n\n<p>* Patients were considered to have high-risk disease based on the criteria used in the monarchE trial: \u2265 4 positive axillary lymph nodes or 1\u20133 positive axillary lymph nodes and tumors that were \u2265 5 cm, histological grade 3, or both.<sup>1,2<\/sup><\/p>\n\n\n\n<p><strong>References<\/strong><\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Johnston S, et al. Overall Survival with Abemaciclib in Early Breast Cancer, Annals of Oncology (2025), doi: <a href=\"https:\/\/doi.org\/10.1016\/j.annonc.2025.10.005\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1016\/j.annonc.2025.10.005<\/a>.<\/li>\n\n\n\n<li>&nbsp;&nbsp;Rastogi, P., et al. (2024) Journal of Clinical Oncology: JCO.23.01994.<\/li>\n\n\n\n<li>&nbsp;Hortobagyi GN et al. Ann Oncol. 2025;36(2):149-57.&nbsp;<\/li>\n\n\n\n<li>Verzenios. Summary of Product Characteristics. <a href=\"http:\/\/www.swissmedicinfo.ch\" target=\"_blank\" rel=\"noopener\">www.swissmedicinfo.ch<\/a><\/li>\n\n\n\n<li>Swiss Specialities List (SL): <a href=\"http:\/\/www.spezialitaetenliste.ch\" target=\"_blank\" rel=\"noopener\">www.spezialitaetenliste.ch<\/a><\/li>\n<\/ol>\n\n\n\n<p><em>Healthcare professionals can request the references from the company at any time.<\/em><\/p>\n\n\n\n<hr class=\"wp-block-separator alignfull has-text-color has-alpha-channel-opacity has-background is-style-wide\" style=\"background-color:#1b94d9;color:#1b94d9\"\/>\n\n\n\n<h4 id=\"now-available-7-year-monarche-results\" class=\"wp-block-heading\">NOW AVAILABLE! 7-Year MonarchE Results<\/h4>\n\n\n\n<p>Overall Survival and IDFS Outcome<\/p>\n\n\n\n<p>In node-positive, high-risk*, HR+, HER2- EBC, only Verzenios<strong>\u00ae<\/strong> is proven to increase survival and deliver long-lasting protection from recurrence with 2 years of treatment.<sup> \u2020,1-3<\/sup><\/p>\n\n\n\n<p class=\"has-text-align-center\"><strong>If you want to learn more about the latest OS Data, you can watch these recordings here&nbsp;!<\/strong><\/p>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-bottom is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full\"><a href=\"https:\/\/eur03.safelinks.protection.outlook.com\/?url=https%3A%2F%2Faccount.lilly.com%2Fde-CH%2Fsignin%2F%3Ftoken_required%26title%3DMonarchE%2520highlights%2520-%2520BC%2520Talks%2520nov.%25202025%2520recording%26url%3Dhttps%3A%2F%2Fwww.lillyplay.ch%2Fcontent-watch%2F1_x8ad2x25%2FCON12733%3Futm_source%3DLilly%26utm_medium%3DOther&amp;data=05%7C02%7Cdevin.anderhalden%40medizinonline.ch%7C1b319c911992470972be08de80547abd%7C3bdd0da5a0804ccc9147abe61d0f3b04%7C0%7C0%7C639089297793026081%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=h00kARSxQLNMrbWtQKLqT5EQtrQgaIT0MQBAYgqRa88%3D&amp;reserved=0\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" width=\"508\" height=\"616\" data-src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/03\/Screenshot-2026-03-30-at-22.19.17.png\" alt=\"\" class=\"wp-image-552681 lazyload\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 508px; --smush-placeholder-aspect-ratio: 508\/616;\" \/><\/a><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full\"><a href=\"https:\/\/eur03.safelinks.protection.outlook.com\/?url=https%3A%2F%2Faccount.lilly.com%2Fde-CH%2Fsignin%2F%3Ftoken_required%26title%3DMonarchE%2520study%2520highlights%2520-%2520at%2520ESMO%2520by%2520Dr.%2520Marcus%2520Vetter%26url%3Dhttps%3A%2F%2Fwww.lillyplay.ch%2Fcontent-watch%2F1_o80gksuf%2FCON12735%3Futm_source%3DLilly%26utm_medium%3DOther&amp;data=05%7C02%7Cdevin.anderhalden%40medizinonline.ch%7C1b319c911992470972be08de80547abd%7C3bdd0da5a0804ccc9147abe61d0f3b04%7C0%7C0%7C639089297793059523%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=u8I2hHqCk4c2UUxKYUS9cUi8xAUpqLTdZGOe0k6iVx4%3D&amp;reserved=0\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" width=\"502\" height=\"610\" data-src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/03\/Screenshot-2026-03-30-at-22.19.23.png\" alt=\"\" class=\"wp-image-552682 lazyload\" style=\"--smush-placeholder-width: 502px; --smush-placeholder-aspect-ratio: 502\/610;aspect-ratio:0.8229620889550094\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" \/><\/a><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full\"><a href=\"https:\/\/eur03.safelinks.protection.outlook.com\/?url=https%3A%2F%2Faccount.lilly.com%2Fde-CH%2Fsignin%2F%3Ftoken_required%26title%3DMonarchE%2520Overall%2520Survival%2520data%2520-%2520by%2520Prof.%2520Cornelia%2520Leo%26url%3Dhttps%3A%2F%2Fwww.lillyplay.ch%2Fcontent-watch%2F1_k168g9l6%2FCON12734%3Futm_source%3DLilly%26utm_medium%3DOther&amp;data=05%7C02%7Cdevin.anderhalden%40medizinonline.ch%7C1b319c911992470972be08de80547abd%7C3bdd0da5a0804ccc9147abe61d0f3b04%7C0%7C0%7C639089297793081028%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=GWPYsBkfd6H1n9hs4Vg9c3LlNEkhssVwfhuw0yHMvyc%3D&amp;reserved=0\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" width=\"502\" height=\"610\" data-src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/03\/Screenshot-2026-03-30-at-22.19.31.png\" alt=\"\" class=\"wp-image-552683 lazyload\" style=\"--smush-placeholder-width: 502px; --smush-placeholder-aspect-ratio: 502\/610;aspect-ratio:0.8229620889550094\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" \/><\/a><\/figure>\n<\/div>\n<\/div>\n\n\n\n<p>*Verzenios in combination with ET (AI or tamoxifen) is indicated for the adjuvant treatment of adult female patients with HR+, HER2\u2212, node-positive EBC at a high risk of recurrence. High-risk EBC in Cohort 1 was defined as patients who had \u22654 positive nodes or 1\u20133 positive nodes and tumors that were \u22655 cm, histological Grade 3\u2014or both.<sup>5<\/sup>&nbsp; \u2020 A statistically significant OS benefit was seen in the ITT population. Following regulatory consultation at the primary IDFS analysis, the OS analysis plan was amended to increase final events from 390 to 650 to ensure \u22655 years\u2019 follow-up. Verzenios is approved for Cohort 1 (91% of ITT); OS analysis in this subpopulation was not powered or alpha-controlled.<sup>1,3<\/sup>&nbsp;<\/p>\n\n\n\n<p><strong>References<\/strong><\/p>\n\n\n\n<p>1. Johnston S, et al. Overall Survival with Abemaciclib in Early Breast Cancer, Annals of Oncology (2025), doi: https:\/\/doi.org\/10.1016\/j.annonc.2025.10.005. 2. Verzenios. Summary of Product Characteristics. <a href=\"http:\/\/www.swissmedicinfo.ch\" target=\"_blank\" rel=\"noopener\">www.swissmedicinfo.ch<\/a> <strong>3<\/strong>. Rastogi P et al. J Clin Oncol. 2024;42(9):987-93. 4. &nbsp;Hortobagyi GN et al. Ann Oncol. 2025;36(2):149-57.&nbsp;<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-vivid-cyan-blue-color has-alpha-channel-opacity has-vivid-cyan-blue-background-color has-background is-style-wide cnvs-block-core-separator-1775079386572\"\/>\n\n\n\n<h4 id=\"indication1\" class=\"wp-block-heading\">Indication<sup>1<\/sup><\/h4>\n\n\n\n<h4 id=\"verzenios-is-a-cdk46-inhibitor-indicated-for\" class=\"wp-block-heading\">Verzenios\u00ae is a CDK4&amp;6 inhibitor indicated for:<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>The adjuvant treatment of HR+, HER2\u2212, node-positive early breast cancer at high risk<sup>*<\/sup> of relapse based on lymph node status, primary tumour size and tumour grade.<\/strong><\/li>\n\n\n\n<li>Verzenios\u00ae in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) in adult female patients at high risk of recurrence*<\/li>\n\n\n\n<li><strong>&nbsp;In pre- or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with an LHRH agonist Indication<\/strong><\/li>\n<\/ul>\n\n\n\n<p>In EBC, Swiss approval was granted based on the MonarchE&nbsp;<strong>Cohort 1<\/strong>, which represents&nbsp;<strong>91% of the ITT population**<\/strong>.<sup>2,3<\/sup><\/p>\n\n\n\n<p><strong>Cohort 1 inclusion criteria:<sup>2<\/sup><\/strong><sup><\/sup><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>1 to 3 positive axillary lymph nodes&nbsp;<strong>and<\/strong>&nbsp;tumor size \u2265 5 cm&nbsp;<strong>OR<\/strong><\/li>\n\n\n\n<li>1 to 3 positive axillary lymph nodes&nbsp;<strong>and<\/strong>&nbsp;histological tumor grade 3&nbsp;<strong>OR<\/strong><\/li>\n\n\n\n<li>\u2265 4 positive axillary lymph nodes<\/li>\n<\/ul>\n\n\n\n<p><strong>Verzenios\u00ae is a CDK4&amp;6 inhibitor indicated for:<\/strong><\/p>\n\n\n\n<p>\u2022 The treatment of HR+, HER2- <strong>locally advanced or metastatic breast cancer<\/strong><\/p>\n\n\n\n<p>\u2022 Verzenios\u00ae in combination with an aromatase inhibitor as primary ET or in combination with fulvestrant in patients who have previously under-gone ET<\/p>\n\n\n\n<p>\u2022 as monotherapy following disease progression after endocrine therapy and one or two chemotherapy regimens in the metastatic setting, when chemotherapy is not suitable.<\/p>\n\n\n\n<p>\u2022 In pre- or perimenopausal women, endocrine therapy should be combined with an LHRH agonist<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p class=\"has-small-font-size\">* Patients were considered to have high-risk disease based on the criteria used in the monarchE trial: \u2265 4 positive axillary lymph nodes or 1\u20133 positive axillary lymph nodes and tumors that were \u2265 5 cm, histological grade 3, or both.<sup>2,3<\/sup><\/p>\n\n\n\n<p class=\"has-small-font-size\"><sup>++<\/sup>In Cohort 1 0.6 % of patients were male. Male population is excluded for the Swiss approval.<\/p>\n\n\n\n<p class=\"has-small-font-size\"><strong>References<\/strong><\/p>\n\n\n\n<p class=\"has-small-font-size\">1. Verzenios. Summary of Product Characteristics. <a href=\"http:\/\/www.swissmedicinfo.ch\" target=\"_blank\" rel=\"noopener\">www.swissmedicinfo.ch<\/a>, 2. Johnston S, et al. Overall Survival with Abemaciclib in Early Breast Cancer, Annals of Oncology (2025), doi: <a href=\"https:\/\/doi.org\/10.1016\/j.annonc.2025.10.005\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1016\/j.annonc.2025.10.005<\/a>. 3. National Comprehensive Cancer Network. Breast Cancer (Version 1.2024). Available at: www.nccn.org Accessed 7 March 2025.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-vivid-cyan-blue-color has-alpha-channel-opacity has-vivid-cyan-blue-background-color has-background is-style-wide cnvs-block-core-separator-1775079589083\"\/>\n\n\n\n<h4 id=\"risk-of-recurrence-in-ebc\" class=\"wp-block-heading\">Risk of recurrence in EBC<\/h4>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" width=\"920\" height=\"502\" data-src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/EBC.png\" alt=\"\" class=\"wp-image-552850 lazyload\" style=\"--smush-placeholder-width: 920px; --smush-placeholder-aspect-ratio: 920\/502;aspect-ratio:1.8326725139172575;width:601px;height:auto\" data-srcset=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/EBC.png 920w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/EBC-800x437.png 800w\" data-sizes=\"(max-width: 920px) 100vw, 920px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" \/><\/figure>\n\n\n\n<p><strong>References<\/strong> 6. Cheng L et al. Cancer Epidemiol Biomarkers Prev. 2012;21(5):800-9.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-vivid-cyan-blue-color has-alpha-channel-opacity has-vivid-cyan-blue-background-color has-background is-style-wide cnvs-block-core-separator-1775079825106\"\/>\n\n\n\n<p><strong>Breakthrough overall survival data: Verzenios\u00ae in combination with AI or tamoxifen increases survival<sup>\u2020,1<\/sup><\/strong><\/p>\n\n\n\n<p class=\"has-background\" style=\"background-color:#b8dcfa\"><strong>Efficacy (Cohort 1**) \u2502 Overall survival benefit at 7 years<sup>1<\/sup><\/strong><\/p>\n\n\n\n<p>Verzenios<strong>\u00ae<\/strong> is the only CDK4&amp;6 inhibitor with a proven overall survival benefit in the curative setting and 2 years of treatment<sup>\u2020, *,1,2<\/sup><\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"2052\" height=\"1116\" data-src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/001.png\" alt=\"\" class=\"wp-image-552880 lazyload\" data-srcset=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/001.png 2052w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/001-800x435.png 800w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/001-1160x631.png 1160w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/001-1536x835.png 1536w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/001-2048x1114.png 2048w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/001-1120x609.png 1120w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/001-1600x870.png 1600w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/001-1920x1044.png 1920w\" data-sizes=\"(max-width: 2052px) 100vw, 2052px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 2052px; --smush-placeholder-aspect-ratio: 2052\/1116;\" \/><\/figure>\n\n\n\n<p class=\"has-background\" style=\"background-color:#b8dcfa\"><strong><strong>Efficacy (Cohort 1**) \u2502 IDFS benefit at 7 years<sup>1<\/sup><\/strong><\/strong><\/p>\n\n\n\n<p>Verzenios<strong>\u00ae<\/strong> delivers 7 years of sustained IDFS benefit with 2 years of treatment<sup>*,1<\/sup><\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"1800\" height=\"994\" data-src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/002.png\" alt=\"\" class=\"wp-image-552882 lazyload\" data-srcset=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/002.png 1800w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/002-800x442.png 800w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/002-1160x641.png 1160w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/002-1536x848.png 1536w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/002-1120x618.png 1120w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/002-1600x884.png 1600w\" data-sizes=\"(max-width: 1800px) 100vw, 1800px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 1800px; --smush-placeholder-aspect-ratio: 1800\/994;\" \/><\/figure>\n\n\n\n<p><strong>Verzenios<\/strong><strong>\u00ae delivers long-lasting protection &#8211; reducing the risk of recurrence to incurable metastatic disease (Cohort 1**)<sup>1*<\/sup><\/strong><\/p>\n\n\n\n<p>&nbsp;DRFS benefit sustained at 7 years<sup>1<\/sup><\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" width=\"1160\" height=\"649\" data-src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/Screenshot-2026-04-02-at-07.02.58-1160x649.png\" alt=\"\" class=\"wp-image-552897 lazyload\" style=\"--smush-placeholder-width: 1160px; --smush-placeholder-aspect-ratio: 1160\/649;aspect-ratio:1.7287614802809292;width:778px;height:auto\" data-srcset=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/Screenshot-2026-04-02-at-07.02.58-1160x649.png 1160w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/Screenshot-2026-04-02-at-07.02.58-800x448.png 800w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/Screenshot-2026-04-02-at-07.02.58-1536x860.png 1536w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/Screenshot-2026-04-02-at-07.02.58-1120x627.png 1120w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/Screenshot-2026-04-02-at-07.02.58-1600x896.png 1600w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/Screenshot-2026-04-02-at-07.02.58.png 1772w\" data-sizes=\"(max-width: 1160px) 100vw, 1160px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" \/><\/figure>\n\n\n\n<p><strong>~30% fewer <sup>1<\/sup>patients in the abemaciclib arm developed and are living with metastatic disease (Cohort 1**)<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"766\" height=\"374\" data-src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/8u799.png\" alt=\"\" class=\"wp-image-552860 lazyload\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 766px; --smush-placeholder-aspect-ratio: 766\/374;\" \/><\/figure>\n\n\n\n<p class=\"has-text-align-right has-small-font-size\">adapted from Johnston S, et al., 2025<\/p>\n\n\n\n<p class=\"has-small-font-size\"><strong>References<\/strong><\/p>\n\n\n\n<p class=\"has-small-font-size\"><strong>1. <\/strong>Johnston S, et al. Overall Survival with Abemaciclib in Early Breast Cancer, Annals of Oncology (2025), doi: https:\/\/doi.org\/10.1016\/j.annonc.2025.10.005. <strong>2. <\/strong>Hortobagyi GN et al. Ann Oncol. 2025;36(2):149-57.<\/p>\n\n\n\n<p class=\"has-small-font-size\">*Verzenios<strong>\u00ae<\/strong> in combination with ET (AI or tamoxifen) is indicated for the adjuvant treatment of adult female patients with HR+, HER2\u2212, node-positive EBC at a high risk of recurrence. High-risk EBC in Cohort 1 was defined as patients who had \u22654 positive nodes or 1\u20133 positive nodes and tumors that were \u22655 cm, histological Grade 3\u2014or both.<sup>5<\/sup> \u2020A statistically significant OS benefit was seen in the ITT population. Following regulatory consultation at the primary IDFS analysis, the OS analysis plan was amended to increase final events from 390 to 650 to ensure \u22655 years\u2019 follow-up. Verzenios is approved for Cohort 1 (91% of ITT); OS analysis in this subpopulation was not powered or alpha-controlled.<sup>1-3<\/sup><\/p>\n\n\n\n<p class=\"has-small-font-size\"><sup>++<\/sup>In Cohort 1 0.6 % of patients were male. Male population is excluded for the Swiss approval.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-vivid-cyan-blue-color has-alpha-channel-opacity has-vivid-cyan-blue-background-color has-background is-style-wide cnvs-block-core-separator-1775080607938\"\/>\n\n\n\n<p><strong>Treatment Adherence and Dose Adjustments<\/strong><\/p>\n\n\n\n<p>A significant proportion of patients required dose reductions during the 2-year treatment period. Importantly, efficacy was maintained even in those who received reduced doses, highlighting the flexibility of the regimen and its tolerability in real-world settings (Cohort1**).<sup>5<\/sup><\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" width=\"722\" height=\"480\" data-src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/last.png\" alt=\"\" class=\"wp-image-552862 lazyload\" style=\"--smush-placeholder-width: 722px; --smush-placeholder-aspect-ratio: 722\/480;aspect-ratio:1.5041746104792584;width:633px;height:auto\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" \/><\/figure>\n\n\n\n<p class=\"has-small-font-size\">*44% of patients received a dose reduction to help them remain on treatment.<sup>2,5 <\/sup>\u2020 Cohort 1 included patients who had \u22654 positive nodes or 1-3 positive nodes and tumors that were \u22655 cm, histological Grade 3, or both.<sup>5<\/sup><\/p>\n\n\n\n<p class=\"has-small-font-size\"><sup>++<\/sup>In Cohort 1 0.6 % of patients were male. Male population is excluded for the Swiss approval.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-vivid-cyan-blue-color has-alpha-channel-opacity has-vivid-cyan-blue-background-color has-background is-style-wide cnvs-block-core-separator-1775080866148\"\/>\n\n\n\n<h4 id=\"safety-profile\" class=\"wp-block-heading\">Safety Profile<\/h4>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"2124\" height=\"1144\" data-src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/006.png\" alt=\"\" class=\"wp-image-552879 lazyload\" data-srcset=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/006.png 2124w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/006-800x431.png 800w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/006-1160x625.png 1160w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/006-1536x827.png 1536w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/006-2048x1103.png 2048w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/006-1120x603.png 1120w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/006-1600x862.png 1600w, https:\/\/medizinonline.com\/wp-content\/uploads\/2026\/04\/006-1920x1034.png 1920w\" data-sizes=\"(max-width: 2124px) 100vw, 2124px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 2124px; --smush-placeholder-aspect-ratio: 2124\/1144;\" \/><\/figure>\n\n\n\n<p class=\"has-small-font-size\"><strong>References<\/strong><\/p>\n\n\n\n<p class=\"has-small-font-size\">1. Verzenios\u00ae Summary of Product Characteristic. <a href=\"http:\/\/www.swissmedicinfo.ch\" target=\"_blank\" rel=\"noopener\">www.swissmedicinfo.ch<\/a>. 2. Rastogi P, et al. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. <em>J Clin Oncol.<\/em> 2024 Mar 20;42(9):987-993. 3. Johnston SRD, et al. Abemaciclib plus Endocrine Therapy for Hormone Receptor-Positive, HER2-negative, Node-Positive, High-Risk Early Breast Cancer (monarchE): Results from a Preplanned Interim Analysis of a Randomised, Open-Label, Phase 3 Trial. <em>Lancet Oncol.<\/em> 2023 Jan;24(1):77-90. 4. Rugo HS, et al. Adjuvant Abemaciclib Combined with Endocrine Therapy for High-Risk Early Breast Cancer: Safety and Patient-Reported Outcomes from the monarchE Study. <em>Ann Oncol.<\/em> 2022 Jun;33(6):616-627.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-vivid-cyan-blue-color has-alpha-channel-opacity has-vivid-cyan-blue-background-color has-background is-style-wide cnvs-block-core-separator-1775081050334\"\/>\n\n\n\n<h4 id=\"want-to-learn-more\" class=\"wp-block-heading\">Want to learn more<\/h4>\n\n\n\n<div style=\"display:flex;flex-wrap:wrap;gap:20px;justify-content:center;margin:20px 0;\">\n\n  <a href=\"https:\/\/dw250ad2fwsz1.cloudfront.net\/962a1cfe-f9f4-4134-8c11-1f2de1c4386d\/c2545c0e-8a26-41a4-a3e4-21d3165681a2\/c2545c0e-8a26-41a4-a3e4-21d3165681a2_source__v.pdf\" style=\"display:flex;align-items:center;justify-content:center;width:160px;height:180px;background:#129dcd;border:2px solid #1d3d57;border-radius:24px;text-decoration:none;padding:14px;box-sizing:border-box;\" target=\"_blank\" rel=\"noopener\">\n    <span style=\"color:#fff;font-family:Arial, Helvetica, sans-serif;font-size:14px;line-height:1.3;font-weight:700;text-align:center;text-transform:uppercase;\">\n      Click to<br>the EBC<br>patient<br>brochure\n    <\/span>\n  <\/a>\n\n  <a href=\"https:\/\/dw250ad2fwsz1.cloudfront.net\/962a1cfe-f9f4-4134-8c11-1f2de1c4386d\/d686e21d-ff8b-40c0-839c-0bb626612b2b\/d686e21d-ff8b-40c0-839c-0bb626612b2b_source__v.pdf\" style=\"display:flex;align-items:center;justify-content:center;width:160px;height:180px;background:#129dcd;border:2px solid #1d3d57;border-radius:24px;text-decoration:none;padding:14px;box-sizing:border-box;\" target=\"_blank\" rel=\"noopener\">\n    <span style=\"color:#fff;font-family:Arial, Helvetica, sans-serif;font-size:14px;line-height:1.3;font-weight:700;text-align:center;text-transform:uppercase;\">\n      Click to<br>learn more<br>about dose<br>reduction\n    <\/span>\n  <\/a>\n\n  <a href=\"https:\/\/dw250ad2fwsz1.cloudfront.net\/962a1cfe-f9f4-4134-8c11-1f2de1c4386d\/8527af12-6d00-4997-97ad-adf68965e3ed\/8527af12-6d00-4997-97ad-adf68965e3ed_source__v.pdf\" style=\"display:flex;align-items:center;justify-content:center;width:160px;height:180px;background:#129dcd;border:2px solid #1d3d57;border-radius:24px;text-decoration:none;padding:14px;box-sizing:border-box;\" target=\"_blank\" rel=\"noopener\">\n    <span style=\"color:#fff;font-family:Arial, Helvetica, sans-serif;font-size:14px;line-height:1.3;font-weight:700;text-align:center;text-transform:uppercase;\">\n      Click to<br>learn more<br>about the<br>7-year data\n    <\/span>\n  <\/a>\n\n  <a href=\"https:\/\/dw250ad2fwsz1.cloudfront.net\/962a1cfe-f9f4-4134-8c11-1f2de1c4386d\/ca2a5c5f-2615-46b4-8434-5403109bc563\/ca2a5c5f-2615-46b4-8434-5403109bc563_source__v.pdf\" style=\"display:flex;align-items:center;justify-content:center;width:180px;height:180px;background:#129dcd;border:2px solid #1d3d57;border-radius:24px;text-decoration:none;padding:14px;box-sizing:border-box;\" target=\"_blank\" rel=\"noopener\">\n    <span style=\"color:#fff;font-family:Arial, Helvetica, sans-serif;font-size:14px;line-height:1.3;font-weight:700;text-align:center;text-transform:uppercase;\">\n      Click to see<br>the diarrhea<br>management<br>patient brochure\n    <\/span>\n  <\/a>\n\n<\/div>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" data-src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2025\/02\/lilly_new_logo-1160x370.png\" alt=\"\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" style=\"--smush-placeholder-width: 1160px; --smush-placeholder-aspect-ratio: 1160\/370;\" \/><\/figure>\n\n\n\n<figure class=\"wp-block-table has-small-font-size\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Healthcare Professionals can request the references from the company at any time.&nbsp;<\/strong><\/td><\/tr><tr><td><br>&nbsp;Eli Lilly (Suisse) SA, Chemin des Coquelicots 16, P.O. 580, CH-1214 Vernier&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CMAT-12873\/02.2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"has-small-font-size\"><strong>Abbreviations<\/strong>: AE=adverse event; AI=aromatase inhibitor; CDK4&amp;6i=cyclin-dependent kinase 4&amp;6 inhibitor; CI=confidence interval; DRFS=distant relapse-free survival; EBC=early breast cancer; EMA=European Medicines Agency; ET=endocrine therapy; HER2\u2212=human epidermal growth factor receptor 2-negative; HR+=hormone receptor-positive; HR=hazard ratio; IDFS=invasive disease-free survival; KM=Kalpan-Meier; QoL=quality of life; SL=specialties list.<\/p>\n\n\n\n<p class=\"has-small-font-size\"><strong>Verzenios\u00ae (abemaciclib) film-coated tablets<\/strong> I: Temporarily authorized indication: Adjuvant treatment in combination with endocrine therapy (ET) of adult women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of relapse based on lymph node status, primary tumour size and tumour grade. In pre- or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a LHRH agonist. Permanent Indication: Treatment of postmenopausal women with HR+, HER2- locally advanced or metastatic breast cancer: in combination with an aromatase inhibitor as initial endocrine-based therapy or in combination with fulvestrant in women who have received prior endocrine therapy. As monotherapy following disease progression after endocrine therapy and one or two chemotherapy regimens in the metastatic setting, when chemotherapy is not suitable. In pre- or perimenopausal women combined with a LHRH-agonist. P: The recommended dose is 150 mg twice daily when used in combination with endocrine therapy and as a single agent 200 mg twice daily.CI: Hypersensitivity. W\/P: For women who have not received any (neo-) adjuvant chemotherapy before, the available data is limited, because only 2% of women in the monarchE study were included. No statistically significant overall survival benefit from abemaciclib was shown at temporary approval. Its impact on survival compared to later relapse treatment, or on subsequent advanced cancer therapies, remains unassessed. Neutropenia, infections, Interstitial Lung Disease (ILD)\/Pneumonitis, diarrhea, increased aminotransferases, venous thromboembolism and arterial thromboembolic events occurred. Contains lactose. Verzenios can have an influence on the ability to drive and use machines. IA: Abemaciclib and its circulating active metabolites resulted in a down-regulation of CYPs\u2019 mRNA, including CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2D6, and CYP3A4 in vitro. In a clinical drug interaction study in women with cancer, multiple doses of abemaciclib did not result in clinically meaningful changes in the pharmacokinetics of CYP1A2 (caffeine), CYP2C9 (S-warfarin), CYP2D6 (dextromethorphane) and CYP3A4 substrates (midazolam). The clinical effects of CYP2C8 and CYP2B6 down regulation are unknown. Abemaciclib is a substrate of CYP3A4, time dependent changes in pharmacokinetics of abemaciclib as a result of autoinhibition of its metabolism were not observed. When strong CYP3A4 inhibitors such as for example clarithromycin, itraconazole, ketoconazole, lopinavir\/ritonavir, posaconazole or voriconazole need to be co-administered, the dose of abemaciclib should be reduced. Caution and monitoring of toxicity is recommended during concomitant treatment with sensitive substrates of P-gp or BCRP that have a narrow therapeutic index, such as digoxin and dabigatran. Sensitive substrates of P-gp or BCRP that do not have a narrow therapeutic index such as pitavastatin, pravastatin and rosuvastatin may be used with caution. Abemaciclib and its major active metabolites inhibit the renal transporters OCT2, MATE1, and MATE2-K at concentrations achievable at the approved recommended dosage. Pr\/L: There are no data from the use of abemaciclib in pregnant women. Animal studies have shown reproduction toxicity. Therefore, Verzenios should not be used during pregnancy and in women of childbearing potential without use of contraception, unless this is absolutely necessary. If Verzenios is used during pregnancy or if a patient gets pregnant during therapy, the patient should be advised of the potential risk for the fetus. It is unknown whether abemaciclib is excreted in human milk. A risk to newborns\/infants cannot be excluded. Women should not breast-feed during treatment with abemaciclib and for at least up to 3 weeks after last administration of abemaciclib. ADR: Very common: Infections, neutropenia, anemia, leukopenia, thrombocytopenia, decreased appetite, dysgeusia, dizziness, diarrhea, nausea, abdominal pain, vomiting, stomatitis, alopecia, rash, pruritus, fatigue, pyrexia, increased ASAT\/ALAT. Common: Lacrimation increase, venous thromboembolism, lymphopenia, Interstitial lung disease\/pneumonitis, dry mouth, dry skin, muscular weakness. P: 50 mg, 100 mg, 150 mg, 200 mg: 28 and 56 film-coated tablets. Dispensing category A..<\/p>\n\n\n\n<p class=\"has-small-font-size\">Consult www.swissmedicinfo.ch for further information.<\/p>\n\n\n\n<p class=\"has-small-font-size\">Eli Lilly (Suisse) SA, ch. des Coquelicots 16, CP 580, 1214 Vernier (GE). V12-2023<\/p>\n\n\n\n<p class=\"has-small-font-size\">PP-AL-CH-0757\/09.2025<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<h1>Optimale Behandlungsoptionen f\u00fcr Hochrisiko-HR+, HER2- EBC- Patientinnen<sup>#<\/sup><\/h1>\n<p>Bei HR+, HER2- fr\u00fchem Brustkrebs besteht ein erhebliches Risiko f\u00fcr ein Rezidiv, das oft innerhalb der ersten f\u00fcnf Jahre nach der Diagnose auftritt<sup>#,1<\/sup>. Diese Patientinnen ben\u00f6tigen besondere Aufmerksamkeit und eine ma\u00dfgeschneiderte Therapie, um das Risiko eines R\u00fcckfalls zu minimieren.<\/p>\n","protected":false},"author":11,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"pmpro_default_level":"","footnotes":""},"class_list":["post-449112","page","type-page","status-publish","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-24 04:16:23","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"translation_priority","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"it_IT","wpml_translations":{"pt_PT":{"locale":"pt_PT","id":449113,"slug":"monarche-7-year-data","post_title":"MonarchE 7-Year Data","href":"https:\/\/medizinonline.com\/pt-pt\/monarche-7-year-data\/"},"es_ES":{"locale":"es_ES","id":449114,"slug":"monarche-7-year-data","post_title":"MonarchE 7-Year Data","href":"https:\/\/medizinonline.com\/es\/monarche-7-year-data\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/pages\/449112","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/comments?post=449112"}],"version-history":[{"count":3,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/pages\/449112\/revisions"}],"predecessor-version":[{"id":554089,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/pages\/449112\/revisions\/554089"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/media?parent=449112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}